Faeth Therapeutics (FTH) Accumulated Expenses (2020 - 2026)

Faeth Therapeutics (FTH) has reported Accumulated Expenses for 7 consecutive years, with $5.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accumulated Expenses rose 577.55% year-over-year to $5.3 million; the trailing twelve-month figure through Jun 2026 stood at $5.3 million (up 577.55% YoY), and the FY2025 full-year result was $1.3 million, down 29.86% from the prior year.
• Accumulated Expenses eased to $5.3 million in Q2 2026 per FTH's latest filing, from $5.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $5.4 million in Q1 2026 and bottomed at $514000.0 in Q1 2024.
• Historically, Accumulated Expenses has averaged $1.7 million across 5 years, with a median of $1.2 million in 2025.
• The sharpest annual moves came in 2023 and 2026: Accumulated Expenses sank 38.67% in 2023, then soared 577.55% in 2026.
• Over 5 years, Accumulated Expenses stood at $2.5 million in 2022, then tumbled by 38.67% to $1.5 million in 2023, then grew by 24.64% to $1.9 million in 2024, then fell by 29.86% to $1.3 million in 2025, then jumped by 297.8% to $5.3 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $5.3 million, $5.4 million, and $1.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.